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OBJECTIVE 
To describe the results obtained of the comparative study between both 
versions of the ELISA commercialized for therapeutic drug monitoring of 
Adalimumab (Promonitor®, Proteomika S.L., distribuited by Menarini 
Diagnósticos S.A.®). 
PATIENTS AND METHODS   
•  24 selected samples of patients with rheumatoid arthritis treated with 
Adalimumab (ADA). 
•  With different concentrations of drug that covered the whole analytical 
range of the assay.  
•  The samples were extracted just before the administration of ADA and 
remained frozen to -80ºC (trough level). 
•  They were analyzed for duplicate with both available versions of the 
ELISA: V1 or previous and V2 or updated. 
•  Statistical study: 
      -  t of Student of samples paired to compare ADA's average  
         concentrations between both analysis with the same version of the test.  
      - By means of the statistician kappa the conformity was evaluated  
        between the results obtained with the same version.  
    -  There has been calculated the Coefficient of Correlation of Conformity  
       (CCC) and his interval of confidence to know if the            
       measurements with both versions of the test show conformity.  
  -  Bland-Altman analysis to value the average difference along the whole  
       measured interval. 
CONCLUSIONS  
1. The V2 of the test provides higher results of ADA's concentration that the V1. Nevertheless, a major precision is observed in the range of near concentrations at the level of clinical decision. 





































p = 0,59 p = 0,08 
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0,55 
(0,18 – 0,79) 
0,91 
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CCCC: 0,76 (0,55-0,88) 
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